全文获取类型
收费全文 | 1720篇 |
免费 | 85篇 |
国内免费 | 113篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 78篇 |
妇产科学 | 45篇 |
基础医学 | 179篇 |
口腔科学 | 24篇 |
临床医学 | 199篇 |
内科学 | 419篇 |
皮肤病学 | 41篇 |
神经病学 | 46篇 |
特种医学 | 368篇 |
外国民族医学 | 1篇 |
外科学 | 102篇 |
综合类 | 40篇 |
预防医学 | 199篇 |
眼科学 | 12篇 |
药学 | 97篇 |
中国医学 | 1篇 |
肿瘤学 | 65篇 |
出版年
2023年 | 6篇 |
2022年 | 4篇 |
2021年 | 15篇 |
2020年 | 13篇 |
2019年 | 12篇 |
2018年 | 24篇 |
2017年 | 3篇 |
2016年 | 22篇 |
2015年 | 25篇 |
2014年 | 19篇 |
2013年 | 55篇 |
2012年 | 32篇 |
2011年 | 50篇 |
2010年 | 63篇 |
2009年 | 58篇 |
2008年 | 42篇 |
2007年 | 88篇 |
2006年 | 53篇 |
2005年 | 64篇 |
2004年 | 30篇 |
2003年 | 32篇 |
2002年 | 34篇 |
2001年 | 32篇 |
2000年 | 47篇 |
1999年 | 38篇 |
1998年 | 103篇 |
1997年 | 96篇 |
1996年 | 106篇 |
1995年 | 65篇 |
1994年 | 63篇 |
1993年 | 67篇 |
1992年 | 18篇 |
1991年 | 37篇 |
1990年 | 33篇 |
1989年 | 54篇 |
1988年 | 44篇 |
1987年 | 54篇 |
1986年 | 35篇 |
1985年 | 51篇 |
1984年 | 22篇 |
1983年 | 23篇 |
1982年 | 28篇 |
1981年 | 23篇 |
1980年 | 32篇 |
1979年 | 11篇 |
1978年 | 14篇 |
1977年 | 17篇 |
1976年 | 29篇 |
1975年 | 15篇 |
1934年 | 2篇 |
排序方式: 共有1918条查询结果,搜索用时 31 毫秒
61.
Background
Cardiovascular disease caused by atherosclerosis is the largest single killer of women. Prior observational data had suggested that hormone therapy may have cardioprotective effects.Methods
Data from clinical trials and basic science studies were evaluated to assess the cardiovascular effects of hormone therapy and selective estrogen replacement modulators.Results
Hormone therapy does not appear to lower the risk of cardiovascular events in older postmenopausal women. Selective estrogen receptor modulators (SERMS) have been approved for human use; tamoxifen is used for treatment and prevention of breast cancer and raloxifene is used for the treatment and prevention of osteoporosis. Raloxifene is the only SERM being specifically studied for its effects on coronary heart disease events in a prospective, randomized, controlled trial.Conclusions
Although raloxifene does increase venous thromboembolic events, there is suggestive data that it may have favorable effects on the arterial systems in women. Only compelling positive data from the Raloxifene Use for The Heart (RUTH) trial will lead to greater use of SERMS to potentially lower the risk of atherosclerotic vascular disease. 相似文献62.
Solary E; Witz B; Caillot D; Moreau P; Desablens B; Cahn JY; Sadoun A; Pignon B; Berthou C; Maloisel F; Guyotat D; Casassus P; Ifrah N; Lamy Y; Audhuy B; Colombat P; Harousseau JL 《Blood》1996,88(4):1198-1205
A phase III prospective randomized multicenter study was performed to determine whether quinine could improve the response rate of poor-risk acute leukemias (ALs) to standard chemotherapy including a multidrug resistance (MDR)-related cytotoxic agent. The rationale of the study was based on the negative prognostic value of MDR phenotype in ALs and the ability of quinine to reverse this phenotype both in vitro and ex vivo. Three hundred fifteen patients (median age, 49 years; range, 16 to 65) with relapsed (n = 108) or refractory (n = 32) acute myeloblastic leukemia (AML), relapsed (n = 27) or refractory (n = 9) acute lymphoblastic leukemia (ALL), secondary AL (n = 22) or blastic transformation of myelodysplastic syndrome ([MDS] n = 74) or myeloproliferative syndrome ([MPS] n = 43) were randomly assigned to receive mitoxantrone ([MXN] 12 mg/m2/d, days 2 to 5) and cytarabine ([Ara-C] 1 g/m2/12 h, days 1 to 5) alone or in combination with quinine (30 mg/kg/d, days 1 to 5; continuous intravenous infusion beginning 24 hours before MXN infusion). Side effects of quinine were observed in 56 of 161 quinine-treated patients and disappeared in all but four cases after one or two 20% dose decreases. Sera from quinine-treated patients showed increased MXN uptake in an MDR-positive cell line compared with matched sera obtained before quinine infusion. Quinine induced a significant increase in the incidence of nausea, vomiting, mucositis, and cardiac toxicity. A complete response (CR) was observed in 85 of 161 patients (52.8%) from the quinine-treated group versus 70 of 154 patients (45.5%) in the control group (P = .19). The most important differences between quinine and control group CR rates were observed in patients with refractory AMLs and blastic transformation of MDS and MPS. The CR rate was higher in P-glycoprotein-positive cases, although the difference was not significant. Failure of the regimen due to blastic persistence or blast number increase was higher in the control group (61 of 154 patients) than in the quinine group (45 of 161, P = .04). Early death was observed in eight cases (four in each arm) and death in aplasia in 27 cases (20 in quinine group v seven in control group, P = .01). The significant increase of toxicity in the quinine arm could have masked the clinical benefit of MDR reversion in poor- risk ALs. 相似文献
63.
Dr. John J. Norcini PhD Harry R. Kimball MD Louis J. Grosso MEd Susan C. Day MD Rebecca A. Baranowski MEd Muriel W. Horne 《Journal of general internal medicine》1994,9(7):361-365
Objective: To determine whether changes in the demographic/educational mix of those entering internal medicine from 1986 to 1989 were
associated with differences among them at the time of certification.
Participants: Included in the study were all candidates for the 1989 to 1992 American Board of Internal Medicine certifying examinations
in internal medicine.
Measurements: Demographic information and medical school, residency training, and examination experience were available for each candidate.
Data defining quality, size, and number of subspecialties were available for internal medicine training programs.
Results: From 1990 to 1992, the total number of men and women candidates increased as did the numbers of foreign-citizen non-U.S.
medical school graduates and osteopathic medical school graduates; the number of U.S. medical school graduates remained nearly
constant and the number of U.S.-citizen graduates of non-U.S. medical schools declined. The pass rates for all groups of first-time
examination takers decreased, while the ratings of program directors remained relatively constant. Program quality, size,
and number of subspecialty programs had modest positive relationships with examination performance.
Conclusions: Changes in the characteristics of those entering internal medicine from 1986 to 1989 were associated with declines in performance
at the time of certification. These declines occurred in all content areas of the test and were apparent regardless of program
quality. These data identify some of the challenges internal medicine faces in the years ahead.
Received from the American Board of Internal Medicine, Philadelphia, Pennsylvania.
This research was supported by the American Board of Internal Medicine but does not necessarily reflect its opinions or policies. 相似文献
64.
65.
66.
67.
Liver-derived fetal hematopoietic stem cells selectively and preferentially home to the fetal bone marrow 总被引:4,自引:8,他引:4
In the course of ontogeny, the homing site for the hematopoietic stem cells (HSC) moves with certain predictability from the yolk sac to the liver/spleen and then to the marrow. The pattern of this migration has thus far been established mostly on a morphologic basis. To delineate further the course of this migration and to gain insight into its possible mechanism, we used in utero transplantation of allogeneic or xenogeneic HSC in preimmune sheep fetuses. Sex chromosome, type of hemoglobin, and species-specific surface markers were used to follow the path of transplanted cells in the fetus. Before the development of the bone marrow, transplanted HSC (liver- or marrow-derived) homed exclusively to the liver/spleen. With the development of marrow, around day 60 of gestation (term, 145 days), homing occurred also in the nascent marrow and by day 80 transplanted cells homed exclusively to the marrow. This suggests that there may be a hierarchy in homing sites, with those of the marrow having higher affinity than those of liver/spleen. Interestingly, despite a change in homing that was followed by the expansion of the marrow compartment of HSC (ie, HSC proliferation), these cells did not participate actively in blood cell formation during most of the prenatal period. Liver remained the major hematopoietic organ throughout the gestation. It was only during the perinatal period that this organ assumed the function of hematopoiesis from the liver. This lack of expression of HSC in fetal marrow can possibly be attributable to the immaturity of marrow stroma required for differentiation and maturation of progenitors and the orderly egress of mature cells into the blood stream. The availability of this model allows us to begin studies in the molecular mechanism of stem cell homing in vivo during ontogeny. 相似文献
68.
Autologous bone marrow transplantation for acute myeloid leukemia using busulfan plus etoposide as a preparative regimen 总被引:1,自引:0,他引:1
We have studied the use of a new preparative regimen for the treatment of patients in remission of acute myeloid leukemia (AML) with autologous bone marrow transplantation. Chemotherapy consisted of busulfan 1 mg/kg every 6 hours for 4 days (total dose, 16 mg/kg) on days -7 through -4 followed by an intravenous infusion over 6 to 10 hours of etoposide 60 mg/kg on day -3. Autologous bone marrow, treated in vitro with 100 micrograms/mL of 4-hydroperoxycyclophosphamide, was infused on day 0. We have treated 58 patients up to the age of 60 years, 32 in first remission, 21 in second or third remission, and 5 with primary refractory AML unresponsive to high-dose Ara-C, but achieving remission with aggressive salvage regimens. Of the first remission patients, there has been 1 treatment related death and 5 relapses. With median follow-up of 22 months, the actuarial relapse rate is 22% +/- 9% and disease-free survival is 76% +/- 9% at 3 years. Patients with favorable French-American-British (FAB) subtypes (M3 or M4 EO) did especially well, with no relapses seen in 15 patients observed for a median of 30 months. Actuarial relapse rate at 3 years was 48% for first remission patients with less favorable FAB subtypes. Of patients in second or third remission, there were 5 treatment related deaths and 4 relapses. With median follow-up of 22 months, the actuarial relapse rate is 25% +/- 11% and disease-free survival is 56% +/- 11% at 3 years. Four of five primary refractory patients died during treatment and 1 remains in remission with short follow-up. These preliminary data are very encouraging and, if confirmed, support the use of autologous purged bone marrow transplantation using aggressive preparative regimens as one approach to improve the outcome of adults with AML. 相似文献
69.
A new quantitative immunoperoxidase method is presented for determining absolute amounts of peroxidase and, consequently, surface antigen densities of individual cells in B lymphocytes from normal individuals, from subjects with CLL and prolymphocytic leukemia, and during ontogeny of B lympocytes in the mouse. The following results were observed: (1) The density of B antigenic sites were lower on CLL than on normal B lymphocytes. (2) The B antigens density of leukemic lymphocytes varied less from cell to cell, forming a homogeneous peak on histograms. (3) In a very rare case of CLL, the antigen density was measured at the time of initial diagnosis (22,500 sites or 647 U) and during the development of a blastic crisis (135,000 sites or 2576 U). The cell by cell distribution changed from a homogeneous peak with a low number of antigenic sites per cell to a heterogeneous peak with a high number of antigenic sites per cell. (4) In prolymphocytic leukemia, the density of B antigenic sites was greater than on normal B lymphocytes and much more heterogeneous than on CLL lymphocytes. (5) During ontogeny of B lymphocytes in the mouse, maturation is associated with the appearance of a population of cells of intermediate to high Smig density. The finding of a decrease in, and altered distribution of, surface markers in CLL is compared with these ontologic findings in the mouse, and the concept that a monoclonal B lymphocyte in CLL may be arrested at a particular stage in its differentiation is discussed. 相似文献